EGFR and non-small cell lung carcinoma: Of the two EGFR wild-type NSCLC patients with a E545K mutation in exon 9 of the PIK3CA gene, one patient (case #15, Table 3) has ongoing SD at 3+ months on erlotinib/cetuximab/bevacizumab; the other patient (case #23, Table 3) had SD for 3 months on erlotinib/dasatinib.